DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sinemet CR (Carbidopa / Levodopa) - Published Studies

 
 



Sinemet CR Related Published Studies

Well-designed clinical trials related to Sinemet CR (Carbidopa / Levodopa)

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. [2013]

Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. [2010.12.15]

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. [2010.11]

Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. [2009.07]

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]

Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. [2007.05.11]

Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]

Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. [2004.01]

[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study] [2003.06]

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. [2000.05]

Occlusion and levodopa-carbidopa treatment for childhood amblyopia. [1998.10]

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. [1997]

Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. [1996.07]

International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. [1996.03]

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. [1995.02]

Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. [1994.07]

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. [1994.01]

Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. [1992]

Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. [1992]

Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). [1991.08]

Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. [1991.04]

Sinemet CR in Parkinson's disease. [1991.01]

Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. [1990]

Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. [1989.11]

Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. [1989]

Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. [1988.09]

Well-designed clinical trials possibly related to Sinemet CR (Carbidopa / Levodopa)

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. [2014]

Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. [2011.06]

Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. [2011.04]

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. [2010.05]

Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. [2009.07]

Children show individual night-to-night variability of periodic limb movements in sleep. [2009.04.01]

Children show individual night-to-night variability of periodic limb movements in sleep. [2009.04]

Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. [2008.04.01]

Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. [2008.01]

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. [2007.09]

Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion. [2007.03]

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. [2004.10]

Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. [2004.01]

Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. [2003.05]

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. [2002.03]

Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist. [1997.11]

Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism. [1996.06]

Controversies in the therapy of Parkinson's disease. [1996]

The effect of deprenyl and levodopa on the progression of Parkinson's disease. [1995.11]

Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. [1994.02]

Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. [1993.04]

Hereditary motor and sensory neuropathy with treatable extrapyramidal features. [1992.02]

Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. [1992]

Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. [1992]

The effect of dietary protein on the efficacy of L-dopa: a double-blind study. [1989.04]

Other research related to Sinemet CR (Carbidopa / Levodopa)

Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. [2013]

Levodopa/carbidopa to improve motor function subsequent to brain tumor excision. [2013]

Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease. [2012]

Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. [2011.05]

Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. [2011]

Carbidopa/levodopa pharmacy errors in Parkinson's disease. [2010.12.15]

The place of L-dopa/carbidopa in persistent vegetative state. [2010.11]

Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa(R)) in Sweden. [2010]

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. [2008.12.03]

Acute overdose with controlled-release levodopa-carbidopa. [2008.03]

Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects. [2008]

Carbidopa/levodopa-responsive myoclonus. [2007.02.15]

The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. [2006.07]

Other possibly related research studies

[Prevention and treatment of fluctuations in patients with Parkinson's disease] [2006.12.20]

Levodopa can worsen tremor associated with dystonia. [2006.10]

Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. [2006.03]

[18F]FDOPA PET and clinical features in parkinsonism due to manganism. [2005.04]

Dopa-responsive dystonia presenting as delayed and awkward gait. [2008.04]

Interaction between levodopa and enteral nutrition. [2008.03]

Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol. [2007.01]

Restless legs syndrome. [2008.07.15]

Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms. [2008.12.12]

Restless legs syndrome: diagnostic time-savers, Tx tips. [2009.08]

Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. [2009.04]

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. [2010.05]

Sildenafil induced choreoathetosis in men with Parkinson's disease. [2010.01]

Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. [2010.03]

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety] [2009.08]

The impact of levodopa on quality of life in patients with Parkinson disease. [2010.03]

Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance. [2011.08.15]

Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. [2011.03]

Hemiparkinsonism-hemiatrophy syndrome. [2011.03]

Cutting the Gordian knot: the blockage of the jejunal tube, a rare complication of Duodopa infusion treatment. [2010.04]

Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. [2011.01]

Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. [2010.09]

Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage. [2010.10]

Improvement in drug-induced parkinsonism with electroconvulsive therapy. [2011.06]

Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. [2011.05]

Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. [2012]

Determination of minimal clinically important change in early and advanced Parkinson's disease. [2011]

Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. [2011]

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. [2010]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017